# An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

Study · id `cardio:ct-nct02633293` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02633293](<https://clinicaltrials.gov/study/NCT02633293>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02633293

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 243 participants.

## Technical summary

Registry record NCT02633293. Allocation not applicable; no masking; primary purpose treatment. Start 2016-09-15 (actual); primary completion 2021-08-01 (actual). Results posted on 2022-12-02.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 243 participants (enrolled count; ClinicalTrials.gov record NCT02633293, source copy `cardio:ctgov-nct02633293-2022-12-02`, retrieved 2026-10-31)
- Started: 2016-09-15 (actual) (ClinicalTrials.gov record NCT02633293, source copy `cardio:ctgov-nct02633293-2022-12-02`, retrieved 2026-10-31)
- Primary completion: 2021-08-01 (actual) (ClinicalTrials.gov record NCT02633293, source copy `cardio:ctgov-nct02633293-2022-12-02`, retrieved 2026-10-31)
- Completion: 2021-08-01 (actual) (ClinicalTrials.gov record NCT02633293, source copy `cardio:ctgov-nct02633293-2022-12-02`, retrieved 2026-10-31)
- Results first posted: 2022-12-02 (ClinicalTrials.gov record NCT02633293, source copy `cardio:ctgov-nct02633293-2022-12-02`, retrieved 2026-10-31)
- Countries: United States; Puerto Rico (ClinicalTrials.gov record NCT02633293, source copy `cardio:ctgov-nct02633293-2022-12-02`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02633293-2022-12-02`, retrieved 2026-10-31)

## The registry's words

- Brief title: An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
- Condition: Pulmonary Hypertension
- Condition: Interstitial Lung Disease
- Condition: Combined Pulmonary Fibrosis and Emphysema
- Intervention (Drug): Inhaled Treprostinil
- Lead sponsor: United Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: United Therapeutics (`cardio:org-united-therapeutics`)

## Provenance

Content hash: aa4ec330ea636131ba579e02e8242be42bd58fe0ebd73ddf81a7d249e30bc7d0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
